METTL3 and prostate adenocarcinoma: Analysis of publicly available PCa patient datasets identified that METTL3 and WTAP expression was higher in primary prostate adenocarcinoma than in non-malignant prostate tissue, whereas conversely, METTL14 expression was found to be significantly lower.